Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 29 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

41%

12 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

15 recruiting

Enrollment Performance

Analytics

Phase 3
10(43.5%)
Phase 2
8(34.8%)
N/A
3(13.0%)
Phase 4
2(8.7%)
23Total
Phase 3(10)
Phase 2(8)
N/A(3)
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (29)

Showing 20 of 29 trials
NCT07311772Phase 3Recruiting

Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid

Role: collaborator

NCT07459296Phase 3Recruiting

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

Role: collaborator

NCT07303283Phase 2Not Yet Recruiting

Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma

Role: collaborator

NCT04004871Phase 2Completed

Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma

Role: collaborator

NCT05340270Phase 2Active Not Recruiting

PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma

Role: collaborator

NCT07188584Phase 3Recruiting

Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer

Role: collaborator

NCT06760078Phase 4Not Yet Recruiting

Tranexamic Acid with Intensive Blood Pressure Management in Ultra-Early Intracerebral Hemorrhage

Role: collaborator

NCT05892354Not ApplicableRecruiting

Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy

Role: collaborator

NCT06445088Recruiting

Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma

Role: collaborator

NCT05211232Phase 3Active Not Recruiting

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

Role: collaborator

NCT03024164Recruiting

Stroke Registration of Young Adults in China

Role: collaborator

NCT06203314Recruiting

Epstein-Barr Virus and Cancer Risks

Role: collaborator

NCT03598218Not ApplicableCompleted

Hypofractionated Versus Conventionally Fractionated Radiotherapy for Initial Distant Metastases Nasopharyngeal Carcinoma

Role: collaborator

NCT04085900Recruiting

Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City

Role: collaborator

NCT04072107Phase 2Unknown

EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR)

Role: collaborator

NCT05527470Phase 3Recruiting

Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Role: collaborator

NCT05097209Phase 2Recruiting

Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma

Role: collaborator

NCT05717790Not ApplicableRecruiting

Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma

Role: collaborator

NCT04350190Phase 2Completed

Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Role: collaborator

NCT05447169Recruiting

Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening

Role: collaborator